Dosing in neonates: special considerations in physiology and trial design

Determining the right dose for drugs used to treat neonates is critically important. Neonates have significant differences in physiology affecting drug absorption, distribution, metabolism, and elimination that make extrapolating dosages from adults and older children inappropriate. In spite of recent legislative efforts requiring drug studies in this population, most drugs given to neonates remain insufficiently studied. Many ethical and logistical concerns make designing studies in this age group difficult. Fortunately, specialized analytical techniques, such as the use of dried blood spots, scavenged sampling, population pharmacokinetics analyses, and sparse sampling, have helped investigators better define doses that maximize efficacy and safety. Through the use of these methods, successful clinical trials have resulted in recent changes to drug dosing in this population.

[1]  P. Smith,et al.  Higher clearance of micafungin in neonates compared with adults: role of age‐dependent micafungin serum binding , 2011, Biopharmaceutics & drug disposition.

[2]  A H Neims,et al.  Pharmacokinetic aspects of theophylline in premature newborns. , 1976, The New England journal of medicine.

[3]  B. Poindexter,et al.  Population Pharmacokinetics of Meropenem in Plasma and Cerebrospinal Fluid of Infants With Suspected or Complicated Intra-abdominal Infections , 2011, The Pediatric infectious disease journal.

[4]  G. Koren Therapeutic drug monitoring principles in the neonate. National Academy of CLinical Biochemistry. , 1997, Clinical chemistry.

[5]  M. Rasmussen,et al.  Meropenem Pharmacokinetics, Pharmacodynamics, and Monte Carlo Simulation in the Neonate , 2008, The Pediatric infectious disease journal.

[6]  K. Allegaert,et al.  Neonatal pharmacology: extensive interindividual variability despite limited size. , 2011, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG.

[7]  H. Pandya,et al.  Dexamethasone quantification in dried blood spot samples using LC-MS: The potential for application to neonatal pharmacokinetic studies. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[8]  S. Howie,et al.  Blood sample volumes in child health research: review of safe limits. , 2011, Bulletin of the World Health Organization.

[9]  M. Kuo,et al.  Postnatal development of organic cation transport and mdr gene expression in mouse kidney. , 1992, The Journal of pharmacology and experimental therapeutics.

[10]  B. Poindexter,et al.  Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Ronald N Hines,et al.  The ontogeny of drug metabolism enzymes and implications for adverse drug events. , 2008, Pharmacology & therapeutics.

[12]  J. Ramasethu Complications of vascular catheters in the neonatal intensive care unit. , 2008, Clinics in perinatology.

[13]  M. Laughon,et al.  Drug labeling and exposure in neonates. , 2014, JAMA pediatrics.

[14]  K. Markarian,et al.  Phases of fluid and electrolyte homeostasis in the extremely low birth weight infant. , 1995, Pediatrics.

[15]  E. Kimland,et al.  Off‐Label Drug Use in Pediatric Patients , 2012, Clinical pharmacology and therapeutics.

[16]  D. Notterman,et al.  Alternative routes of drug administration - Advantages and disadvantages (subject review) , 1997 .

[17]  G. Kearns,et al.  Impact of developmental pharmacology on pediatric study design: overcoming the challenges. , 2000, The Journal of allergy and clinical immunology.

[18]  A. Warner Drug use in the neonate: interrelationships of pharmacokinetics, toxicity, and biochemical maturity. , 1986, Clinical chemistry.

[19]  A. Smits,et al.  Drug disposition and clinical practice in neonates: cross talk between developmental physiology and pharmacology. , 2013, International journal of pharmaceutics.

[20]  W. Zempsky Alternative Routes of Drug Administration— Advantages and Disadvantages (Subject Review) , 1998, Pediatrics.

[21]  M. Walsh,et al.  Population Pharmacokinetics of Metronidazole Evaluated Using Scavenged Samples from Preterm Infants , 2012, Antimicrobial Agents and Chemotherapy.

[22]  G. Kearns,et al.  Effect of Diet on the Development of Drug Metabolism by Cytochrome P-450 Enzymes in Healthy Infants , 2006, Pediatric Research.

[23]  J. N. van den Anker,et al.  DEVELOPMENTAL PHARMACOLOGY: NEONATES ARE NOT JUST SMALL ADULTS… , 2008, Acta clinica Belgica.

[24]  K. Oselin,et al.  Short versus Long Infusion of Meropenem in Very-Low-Birth-Weight Neonates , 2012, Antimicrobial Agents and Chemotherapy.

[25]  A. Langslet NEONATAL PHARMACOLOGY , 1974, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke.

[26]  J. McElnay,et al.  Metronidazole Population Pharmacokinetics in Preterm Neonates Using Dried Blood-Spot Sampling , 2011, Pediatrics.

[27]  P. Smith,et al.  Determining Population and Developmental Pharmacokinetics of Metronidazole Using Plasma and Dried Blood Spot Samples From Premature Infants , 2013, The Pediatric infectious disease journal.

[28]  R. Kauffman,et al.  Basics and dynamics of neonatal and pediatric pharmacology. , 2011, Handbook of experimental pharmacology.

[29]  F. Sorgel,et al.  Meropenem Pharmacokinetics in the Newborn , 2009, Antimicrobial Agents and Chemotherapy.

[30]  P. Routledge Pharmacokinetics in children. , 1994, The Journal of antimicrobial chemotherapy.

[31]  P. Smith,et al.  Fluconazole Loading Dose Pharmacokinetics and Safety in Infants , 2011, The Pediatric infectious disease journal.

[32]  H. Mulla Understanding Developmental Pharmacodynamics , 2010, Paediatric drugs.

[33]  H. Pandya,et al.  Dried blood spots and sparse sampling: a practical approach to estimating pharmacokinetic parameters of caffeine in preterm infants. , 2013, British journal of clinical pharmacology.

[34]  Susan M Abdel-Rahman,et al.  Developmental pharmacology--drug disposition, action, and therapy in infants and children. , 2003, The New England journal of medicine.

[35]  F. Guillemin,et al.  Glomerular Filtration Rate Reference Values in Very Preterm Infants , 2010, Pediatrics.

[36]  D. Kaufman,et al.  Pharmacokinetics of an Elevated Dosage of Micafungin in Premature Neonates , 2009, The Pediatric infectious disease journal.

[37]  G. Kearns,et al.  Developmental pharmacokinetics. , 2011, Handbook of experimental pharmacology.

[38]  V. Narendran,et al.  The Ontogeny of Skin. , 2014, Advances in wound care.

[39]  N. Saunders,et al.  Barriers in the developing brain and Neurotoxicology. , 2012, Neurotoxicology.

[40]  P. Smith,et al.  Population Pharmacokinetics of Micafungin in Neonates and Young Infants , 2010, Antimicrobial Agents and Chemotherapy.

[41]  P. Annaert,et al.  The ontogeny of drug metabolizing enzymes and transporters in the rat. , 2008, Reproductive toxicology.

[42]  D. Tibboel,et al.  Ontogeny of Human Hepatic and Intestinal Transporter Gene Expression during Childhood: Age Matters , 2014, Drug Metabolism and Disposition.

[43]  K. Brouwer,et al.  Pharmacokinetics and Safety of Fluconazole in Young Infants Supported With Extracorporeal Membrane Oxygenation , 2012, The Pediatric infectious disease journal.

[44]  M. Laughon,et al.  Innovative clinical trial design for pediatric therapeutics , 2011, Expert review of clinical pharmacology.

[45]  O. Della Pasqua,et al.  Development of paediatric medicines: concepts and principles. , 2011, Handbook of experimental pharmacology.

[46]  A. Zajicek The National Institutes of Health and the Best Pharmaceuticals for Children Act , 2009, Paediatric drugs.

[47]  M. J. Bell,et al.  Pharmacokinetics of clindamycin phosphate in the first year of life. , 1984, The Journal of pediatrics.

[48]  G. Kearns,et al.  The Pharmacokinetics and Safety of Micafungin, a Novel Echinocandin, in Premature Infants , 2006, The Pediatric infectious disease journal.

[49]  M. Walsh,et al.  Population Pharmacokinetics of Piperacillin Using Scavenged Samples From Preterm Infants , 2012, Therapeutic drug monitoring.

[50]  C. Ross,et al.  Gentamicin and verapamil compete for a common transport mechanism in renal brush border membrane vesicles. , 1989, The Journal of pharmacology and experimental therapeutics.

[51]  B. Ali,et al.  Gentamicin nephrotoxicity in humans and animals: some recent research. , 1995, General pharmacology.

[52]  G. Koren,et al.  Clinical pharmacology and therapeutic drug monitoring in neonates and children. , 1998, Pediatrics in review.

[53]  M. Brodie,et al.  Enzyme induction with antiepileptic drugs: Cause for concern? , 2013, Epilepsia.

[54]  B. Anderson Pharmacology in the very young: anaesthetic implications , 2012, European journal of anaesthesiology.

[55]  H. Lafeber,et al.  Pharmacokinetics of Meropenem in Preterm Neonates , 2001, Therapeutic drug monitoring.

[56]  Bill J Smith,et al.  Progress in Brain Penetration Evaluation in Drug Discovery and Development , 2008, Journal of Pharmacology and Experimental Therapeutics.

[57]  D. G. McCarver,et al.  The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. , 2002, The Journal of pharmacology and experimental therapeutics.

[58]  K. Watterberg Evidence-based neonatal pharmacotherapy: postnatal corticosteroids. , 2012, Clinics in perinatology.

[59]  C. Yokoyama,et al.  Developmental Changes in P-Glycoprotein Function in the Blood–Brain Barrier of Nonhuman Primates: PET Study with R-11C-Verapamil and 11C-Oseltamivir , 2011, The Journal of Nuclear Medicine.

[60]  S. Jadcherla,et al.  Effect of Erythromycin on Gastroduodenal Contractile Activity in Developing Neonates , 2002, Journal of pediatric gastroenterology and nutrition.

[61]  D. Kaufman,et al.  Fluconazole Dosing for the Prevention or Treatment of Invasive Candidiasis in Young Infants , 2009, The Pediatric infectious disease journal.

[62]  D. Azzopardi,et al.  Elevated Morphine Concentrations in Neonates Treated With Morphine and Prolonged Hypothermia for Hypoxic Ischemic Encephalopathy , 2008, Pediatrics.

[63]  R. Hines Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children. , 2013, International journal of pharmaceutics.

[64]  G. Kearns,et al.  Ontogeny of drug metabolizing enzymes in the neonate. , 2005, Seminars in fetal & neonatal medicine.

[65]  Catherine Tom-Revzon Erratic absorption of intramuscular antimicrobial delivery in infants and children , 2007, Expert opinion on drug metabolism & toxicology.

[66]  G. Koren Therapeutic drug monitoring principles in the neonate , 1997 .

[67]  M. Laughon,et al.  Fluconazole pharmacokinetics and safety in premature infants. , 2012, Current medicinal chemistry.

[68]  D. Benjamin,et al.  Role of Flavin-Containing Monooxygenase in Oxidative Metabolism of Voriconazole by Human Liver Microsomes , 2008, Drug Metabolism and Disposition.

[69]  D. Kaufman,et al.  Safety and Pharmacokinetics of Repeat‐Dose Micafungin in Young Infants , 2010, Clinical pharmacology and therapeutics.

[70]  Yi Wang,et al.  Population pharmacokinetics of piperacillin/tazobactam in neonates and young infants , 2013, European Journal of Clinical Pharmacology.

[71]  R. Mcdonald,et al.  Antibiotic sampling from central venous catheters versus peripheral veins. , 2004, Pediatric nursing.

[72]  B. Poindexter,et al.  Developmental Pharmacokinetics of Piperacillin and Tazobactam Using Plasma and Dried Blood Spots from Infants , 2014, Antimicrobial Agents and Chemotherapy.

[73]  J. Ghersi-Egea,et al.  Physiology of blood-brain interfaces in relation to brain disposition of small compounds and macromolecules. , 2013, Molecular pharmaceutics.

[74]  D. Kaufman,et al.  Population Pharmacokinetics of Fluconazole in Young Infants , 2008, Antimicrobial Agents and Chemotherapy.

[75]  P. Smith,et al.  Pharmacokinetics and Tolerability of Single-Dose Daptomycin in Young Infants , 2012, The Pediatric infectious disease journal.